Navigation Links
ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders
Date:9/6/2010

hase III clinical trials for the non-surgical treatment of retinal disorders. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (anti-Factor VIII), a long acting anti-coagulant in Phase II, and TB-403 (anti-PlGF) in Phase Ib/II for cancer in partnership with Roche.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

For further information please contact: ThromboGenics Dr. Steve Pakola, CMO Tel: +1-212-201-0920 steve.pakola@thrombogenics.com Dr. Patrik De Haes, CEO Tel: +32-16-75-13-10 patrik.dehaes@thrombogenics.com Citigate Dewe Rogerson Amber Bielecka/David Dible/Nina Enegren Tel: +44(0)207-638-95-71 amber.bielecka@citigatedr.co.uk
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
10. ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
11. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... WHIPPANY, N.J. , May 4, 2015 ... agreement with Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... clinical development for the prevention of thrombosis. Under the ... in areas of high unmet medical need. As ... evaluate the therapeutic profile of ISIS-FXI Rx in ...
(Date:5/4/2015)... BUFFALO, N.Y. , May 4, 2015 /PRNewswire/ ... Stephanie Englert , PharmD, has completed preliminary analysis ... Disorder and Schizophrenia. Resources from Clinical Support Services, ... Medication Reviews (CMR) with patients currently taking psychiatric ... events. The research found that 93% of patients ...
(Date:5/4/2015)... , May 4, 2015 MEI Pharma, ... focused on the clinical development of novel therapies ... mitochondria-specific effects of the Company,s investigational drug candidate ... activity when combined with a tyrosine-kinase inhibitor (TKI). ... to be a potent inhibitor of mitochondrial oxidative ...
Breaking Medicine Technology:Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5
(Date:5/4/2015)... New findings released today from a poll conducted ... people diagnosed with a brain tumor needed more information ... at the time of diagnosis, and had only a ... course of treatment. The release of these findings corresponds ... volunteer network, the ABTA CommYOUnity™, dedicated to serving the ...
(Date:5/4/2015)... May 04, 2015 Pricing Healthcare ... $3,000) of one patient receiving care at St. George ... The procedure must be performed by July 15th, 2015, and ... in full up front and forego the filing of insurance ... economically burdensome every year, and it devastates more and more ...
(Date:5/4/2015)... New York, NY (PRWEB) May 04, 2015 ... Mother Hale Learning Center from Hale House. The Mother ... by offering high-quality, affordable Early Childhood Education. Sheltering Arms ... families will continue to be served by the center. ... serves 45 children ages six weeks to five years, ...
(Date:5/4/2015)... Helena, MT (PRWEB) May 04, 2015 ... partnered with Care to Care, LLC to manage outpatient ... will help New West Medicare ensure its members are ... avoid unnecessary radiation. , Working closely with New West ... in promoting the safe use of advanced imaging and ...
(Date:5/4/2015)... Elisabeth Rosenthal’s article* on “balance billing” ... the healthcare fraternity as well as patients about ... of balance billing. In definition, balance billing is ... patient for the difference between what the patient's ... provider chooses to charge. Rosenthal’s article talks about ...
Breaking Medicine News(10 mins):Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 3Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2Health News:New West Medicare Partners with Care to Care, LLC to Manage Advanced Imaging Services 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 3
... in US have come up with a heady option that ... in brain cells often after an episode of stroke or ... John Hopkins University ,who conducted a study on mice, ... the skin of red grapes, administered in moderate doses, showed ...
... overweight youngsters lose weight by concentrating on the way they ... make them// gorge even more, according to a recent study. ... motivated to change their eating habits than those who are ... suggest that getting children of all shapes and sizes to ...
... report released, based on the study conducted by epidemiologists ... significant increase in mortality risk among the workers at// ... perfluorooctanoic acid, the key component of the material Teflon. ... company definitely reveals lower mortality rates than West ...
... fever in Kerala will not affect the state's booming tourism ... ,"As the World Health Organisation (WHO) has come out with ... chikungunya, things have cheered up. There have been no reports ... to Kerala," Balakrishnan told reporters here. ,The fever, ...
... despite the fact that few actually need it, says a ... stay healthy is a balanced diet. ,People are often ... fewer nutrients than it used to, said Jane Clarke. The ... reported the online edition of Daily Mail. ...
... Treatment outcomes vary widely and depend on which state, ... the finding of a new report//. ,The report, ... have a 69 percent lower risk of dying at ... the difference between the best- and worst-performing hospitals has ...
Cached Medicine News:Health News:Obese Kids Unmotivated byWeight Loss campaigns 2Health News:Madhya Pradesh Tops in Implementing Child Health Scheme 2Health News:Hospital Outcome Linked to its Quality 2
This portable resource provides definitions for medical acronyms and abbreviations....
Stedman's Medical Dictionary includes charts and tables and navigation and search tools....
With Skyscape's smARTlink technology, Tabers can cross-index with other clinical and drug prescription products from Skyscape to provide an integrated source of clinical information....
CPTMeister is a coding reference based on the Physicians' Current Procedural Terminology (CPT) codes developed by the American Medical Association. It is an iSilo document composed of more than 2,000...
Medicine Products: